t4 workshop reports:
28. Marx, U., Akabane, T., Andersson, T.
B., et al. (2020) “Biology-inspired microphysiological systems to
advance patient benefit and animal welfare in drug development”, ALTEX -
Alternatives to animal experimentation, 37(3), pp. 364-394. doi:
10.14573/altex.2001241.
27. Beilmann, M., Boonen,
H., Czich, A., et al. (2019)
“Optimizing drug discovery by investigative toxicology: Current and future
trends”, ALTEX - Alternatives to animal experimentation, 36(2), pp.
289-313. doi: 10.14573/altex.1808181.
26. Pamies, D., Bal-Price, A., Chesné, et
al. (2018) “Advanced Good Cell Culture Practice for human primary, stem
cell-derived and organoid models as well as microphysiological systems”, ALTEX
- Alternatives to animal experimentation, 35(3), pp. 353-378. doi:
10.14573/altex.1710081.
25. Pamies, D., Bal-Price, A., Chesné, et
al. (2018) “Advanced Good Cell Culture Practice for human primary, stem
cell-derived and organoid models as well as microphysiological systems”, ALTEX
- Alternatives to animal experimentation, 35(3), pp. 353-378. doi:
10.14573/altex.1710081. 24. Myers, D. K.,
Goldberg, A. M., Poth, A., et al. (2017) “From in vivo to in vitro: The
medical device testing paradigm shift”, ALTEX - Alternatives to animal
experimentation, 34(4), pp. 479-500. doi: 10.14573/altex.1608081.
23. Pamies, D., Bal-Price, A., Simeonov,
A., et al. (2017) “Good Cell Culture Practice for stem cells and
stem-cell-derived models”, ALTEX - Alternatives to animal experimentation,
34(1), pp. 95-132. doi: 10.14573/altex.1607121.
22. Aschner, M., Ceccatelli, S.,
Daneshian, M., et al. (2017) “Reference compounds for alternative
test methods to indicate developmental neurotoxicity (DNT) potential of
chemicals: Example lists and criteria for their selection and use”, ALTEX -
Alternatives to animal experimentation, 34(1), pp. 49-74. doi:
10.14573/altex.1604201. 21. Marx, U., Andersson, T. B., Bahinski, A., et al. (2016)
“Biology-inspired microphysiological system approaches to solve the prediction
dilemma of substance testing”, ALTEX - Alternatives to animal
experimentation, 33(3), pp. 272-321. doi: 10.14573/altex.1603161.
28. Zhu, H.,
Bouhifd, M., Donley, E., et al. (2016) “Supporting read-across
using biological data”, ALTEX - Alternatives to animal experimentation,
33(2), pp. 167-182. doi: 10.14573/altex.1601252.
20. Ball, N.,
Cronin, M. T. D., Shen, J., et al. (2016) “Toward Good Read-Across
Practice (GRAP) guidance”, ALTEX - Alternatives to animal experimentation,
33(2), pp. 149-166. doi: 10.14573/altex.1601251.
19. Rovida, C.,
Alépée, N., Api, et al. (2015) “Integrated testing strategies
(ITS) for safety assessment”, ALTEX - Alternatives to animal experimentation,
32(1), pp. 25-40. doi: 10.14573/altex.1411011.
18. Gordon, S.,
Daneshian, M., Bouwstra, J., et al. (2015) “Non-animal models of
epithelial barriers (skin, intestine and lung) in research, industrial
applications and regulatory toxicology”, ALTEX - Alternatives to animal experimentation,
32(4), pp. 327-378. doi: 10.14573/altex.1510051.
17. Bouhifd, M., Beger, R., Flynn, T., et al. (2015)
“Quality assurance of metabolomics”, ALTEX - Alternatives to animal
experimentation, 32(4), pp. 319-326. doi: 10.14573/altex.1509161.
16. Alépée, N.,
Bahinski, A., Daneshian, et al. (2014) “State-of-the-art of 3D cultures (organs-on-a-chip)
in safety testing and pathophysiology”, ALTEX - Alternatives to animal
experimentation, 31(4), pp. 441-477. doi: 10.14573/altex.1406111.
15. van Vliet, E., Daneshian, M., Beilmann, M., et al. (2014)
“Current approaches and future role of high content imaging in safety sciences
and drug discovery”, ALTEX - Alternatives to animal experimentation,
31(4), pp. 479-493. doi: 10.14573/altex.1405271.
14. Leist, M.,
Hasiwa, N., Rovida, C., et al. (2014) “Consensus report on the future of
animal-free systemic toxicity testing”, ALTEX - Alternatives to animal
experimentation, 31(3), pp. 341-356. doi: 10.14573/altex.1406091.
13. Kleensang,
A., Maertens, A., Rosenberg, M., et al. (2014) “Pathways of Toxicity”, ALTEX
- Alternatives to animal experimentation, 31(1), pp. 53-61. doi:
10.14573/altex.1309261.
12. Juberg, D. R., Borghoff, S. J., Becker, R. A., et al. (2014)
“Lessons learned, challenges, and opportunities: The U.S. Endocrine Disruptor
Screening Program”, ALTEX - Alternatives to animal experimentation,
31(1), pp. 63-78. doi: 10.14573/altex.1309171. 11. Juberg,
D.R., Borghoff S.J., Becker R.A., et al. (2014). Lessons
learned, challenges, and opportunities: The U.S. Endocrine Disruptor Screening
Program. ALTEX 31(1), 63–78.
10. Kleensang,
A., Maertens, A., Rosenberg, M., et al. (2014). Pathways of Toxicity. ALTEX 31(1),
53–61. 9. Ramirez,
T., Daneshian, M., Hennicke Kamp H., et al. (2013). Metabolomics in toxicology and preclinical research. ALTEX
30(2), 209–225. 8. Parks
Saldutti L., Beyer B.K., Breslin W., et al. (2013). In vitro testicular toxicity models: Opportunities for
advancement via biomedical engineering techniques. ALTEX 30(3), 353–377. 7. Ramirez, T., Daneshian, M.,
Kamp, H., et al. (2013). Metabolomics in toxicology and preclinical
research. ALTEX 30, 208-225. 6. Blaauboer, B. J., Boekelheide, K., Clewell, H. J., et
al. (2012). The use of biomarkers of toxicity for integrating in vitro
hazard estimates into risk assessment for humans. ALTEX 29, 411-425. 5. Saldutti, L.P., Beyer, B.K., Breslin, W., et al. In
vitro Testicular Toxicity Models: Opportunities for Advancement via Biomedical
Engineering Techniques (2011). Baltimore, Maryland, USA on October 26-27
, submitted. 4. Zurlo, J. ,
Bayne, K. A., Brown, D. C., et al. (2011). Critical evaluation of the use
of dogs in biomedical research and testing. ALTEX 28, 355-359. 3. Silbergeld, E. K., Contreras, E. Q., Hartung, T., et
al. (2011). Nanotoxicology: “The end of the beginning” – Signs on the
roadmap to a strategy for assuring the safe application and use of
nanomaterials – t4 workshop report. ALTEX 28, 236-241. 2. Hasiwa, N., Bailey, J., Clausing, P., et al. (2011).
Critical evaluation of the use of dogs in biomedical research and testing in
Europe. ALTEX 28, 326-340.
1. Daneshian, M., Akbarsha, A. M., Blaauboer, B., et al. (2011).
A framework program for the teaching of alternative methods (replacement,
reduction, refinement) to animal experimentation. ALTEX 28, 341-352.
|
t4 reports:
19. Ferrario, D., Brustio, R. and Hartung, T. (2014) “Glossary
of reference terms for alternative test methods and their validation”, ALTEX
- Alternatives to animal experimentation, 31(3), pp. 319-335. doi:
10.14573/altex.1403311.
18. Daneshian,
M., Botana, L.M., Dechraoui Bottein, MY., (2013). A
roadmap for hazard monitoring and risk assessment of marine biotoxins on the
basis of chemical and biological test systems. ALTEX 30(4), 487–545.
17. Hasiwa, N., Daneshian, M.,
Bruegger, P., et al. (2013). Evidence for the detection of non-endotoxin
pyrogens by the whole blood monocyte activation test. ALTEX 30(2), 169–208 16. Basketter, D.A., Clewell, H.,
Kimber, I., et al. (2012). A roadmap
for the development of alternative (non-animal) methods for systemic toxicity
testing. ALTEX, 29:3-89. 15. Ferrario, D and Rabbit, R. R. (2012).
Analysis of the proposed EU Regulation concerning biocide products and its
opportunities for alternative approaches and a toxicology for the 21st century.
ALTEX 29, 157-172. 14. Basketter, D. A., Clewell, H.,
Kimber, I., et al. (2012). A roadmap for the development of alternative
(non-animal) methods for systemic toxicity testing. ALTEX 29, 3-91. 13. Rovida, C., Longo, F., and
Rabbit, R. R. (2011). How are reproductive toxicity and developmental
toxicity addressed in REACH dossiers? ALTEX
28, 273-294. 12.
Hartung, T., Blaauboer, B. J., Bosgra, S., et al. (2011).
An expert consortium review of the EC-commissioned report “Alternative
(Non-Animal) Methods for Cosmetics Testing: Current Status and Future Prospects
– 2010”. ALTEX 28, 183-209. 11. Boekelheide, K. and Andersen, M. E. (2010).
A mechanistic redefinition of adverse effects – a key step in the toxicity
testing paradigm shift. ALTEX 27,
243-252. 10. Dietrich, D. R. (2010).
Courage for simplification and imperfection in the 21st century assessment of
“Endocrine disruption”. ALTEX 27,
264-278. 9. Jaworska, J. and Hoffmann, S. (2010).
Integrated Testing Strategy (ITS) – Opportunities to better use existing data
and guide future testing in toxicology. ALTEX
27, 231-242. 8.
Hartung T. Vergleichende Analyse der überarbeiteten Richtlinie
2010/63/EU für den Schutz von Labortieren mit der abgelösten Richtlinie
86/609/EEC – ein t4 Bericht. ALTEXethik 2010, 2, 103. 7. Hartung, T. (2010b).
Comparative analysis of the revised Directive 2010/63/EU for the protection of
laboratory animals with its predecessor 86/609/EEC – a t4 report. ALTEX 27, 285-303. 6. Hartung, T. (2010a). Evidence-based toxicology
– the toolbox of validation for the 21st century? ALTEX 27, 253-263. 5. Kuegler, P. B.,
Zimmer, B., Waldmann, T., et al. (2010). Markers of murine embryonic and
neural stem cells, neurons and astrocytes: reference points for developmental
neurotoxicity testing. ALTEX 27,
17-42. 4. Hartung T and Rovida C. Chemical regulators have
overreached. Nature 2009,
460:1080-1081. 3. Rovida C. and
Hartung T. Neuevaluierung der erforderlichen Tierzahlen und Kosten der in vivo
Tests zur Erfüllung der REACH Vorgaben für Chemikalien – ein Bericht des
“transatlantic think tank for toxicology (t4)”. ALTEXethik 2009, 1:115. 2. Rovida, C. and Hartung, T. (2009).
Re-evaluation of animal numbers and costs for in vivo tests to accomplish REACH
legislation requirements for chemicals - a report by the transatlantic think
tank for toxicology (t4). ALTEX 26, 187-208.
1. Leist, M.,
Bremer, S., Brundin, P., et al. (2008). The biological and ethical basis
of the use of human embryonic stem cells for in vitro test systems or cell
therapy. ALTEX 25, 163-190.
|